Acute and subchronic toxicity evaluation of poly(ε-Caprolactone) lipid-core nanocapsules in rats

Toxicological Sciences

Volumn 132, Issue 1, 2013, Pages 162-176

  Bulcão, Rachel P ^a   Freitas, Fernando A ^a   Venturini, Cristina G ^a   Dallegrave, Eliane ^b   Durgante, Juliano ^a   Göethel, Gabriela ^a   Cerski, Carlos Thadeu S ^c   Zielinsky, Paulo ^d   Pohlmann, Adriana R ^a   Guterres, Sílvia S ^a   Garcia, Solange C ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

Author keywords

Biodegradable; In vivo test; Nanotoxicity; Nanotoxicology; Polymeric

Indexed keywords

LIPID CORE NANOCAPSULE; NANOCAPSULE; POLYCAPROLACTONE; POLYSORBATE 80; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ARTICLE; BIODEGRADATION; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FOREIGN BODY REACTION; HEALTH HAZARD; HEMATOLOGICAL PARAMETERS; IN VITRO STUDY; LIVER; LIVER TOXICITY; MATERIAL COATING; NEPHROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; RAT; SPLEEN; SUSPENSION; TOXICITY TESTING; WEIGHT CHANGE;

ANIMALS; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPIDS; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOCAPSULES; ORGAN SIZE; POLYESTERS; RATS; RATS, WISTAR;

RATTUS; RATTUS NORVEGICUS;

EID: 84876492576     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs334     Document Type: Article

References (66)

1. AFSSAPS. (2009). Guidance Document on the AFSSAPS, French Agency for Safety of Health Products. Recommendations for Toxicological Evaluation of Nanoparticle. Available at: http://www.afssaps.fr. Accessed November 2011.
2. AFSSAPS. (2011). Guidance Document on the AFSSAPS, French Agency for Safety of Health Products. Recommendations for Toxicological Evaluation of Nanoparticle. Available at: http://www.afssaps.fr. Accessed November 2011.
3. Bender, E. A., Adorne, M. D., Colomé, L. M., Abdalla, D. S., Guterres, S. S., and Pohlmann, A. R. (2012). Hemocompatibility of poly(?-caprolactone) lipid-core nanocapsules stabilized with polysorbate 80-lecithin and uncoated or coated with chitosan. Int. J. Pharm. 426, 271-279.
4. Bernardi, A., Braganhol, E., Jäger, E., Figueiró, F., Edelweiss, M. I., Pohlmann, A. R., Guterres, S. S., and Battastini, A. M. (2009a). Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 281, 53-63.
5. Bernardi, A., Zilberstein, A. C., Jäger, E., Campos, M. M., Morrone, F. B., Calixto, J. B., Pohlmann, A. R., Guterres, S. S., and Battastini, A. M. (2009b). Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br. J. Pharmacol. 158, 1104-1111.
6. Bernardi, A., Frozza, R. L., Jäger, E., Figueiró, F., Bavaresco, L., Salbego, C., Pohlmann, A. R., Guterres, S. S., and Battastini, A. M. (2008). Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: An in vitro study. Eur. J. Pharmacol. 586, 24-34.
7. Boverhof, D. R., and David, R. M. (2010). Nanomaterial characterization: Considerations and needs for hazard assessment and safety evaluation. Anal. Bioanal. Chem. 396, 953-961.
8. Couvreur, P., Barratt, G., Fattal, E., Legrand, P., and Vauthier, C. (2002). Nanocapsule technology: A review. Crit. Rev. Ther. Drug Carrier Syst. 19, 99-134.
9. Damgé, C., Maincent, P., and Ubrich, N. (2007). Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117, 163-170.
10. Dandekar, P., Dhumal, R., Jain, R., Tiwari, D., Vanage, G., and Patravale, V. (2010). Toxicological evaluation of pH-sensitive nanoparticles of curcumin: Acute, sub-acute and genotoxicity studies. Food Chem. Toxicol. 48, 2073-2089.
11. De Jong, W. H., and Borm, P. J. (2008). Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomedicine 3, 133-149.
12. Dhawan, A., and Sharma, V. (2010). Toxicity assessment of nanomaterials: Methods and challenges. Anal. Bioanal. Chem. 398, 589-605.
13. Doak, S. H., Griffiths, S. M., Manshian, B., Singh, N., Williams, P. M., Brown, A. P., and Jenkins, G. J. (2009). Confounding experimental considerations in nanogenotoxicology. Mutagenesis 24, 285-293.
14. Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., and McNeil, S. E. (2008). Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487-495.
15. Dobrovolskaia, M. A., and McNeil, S. E. (2007). Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2, 469-478.
16. Fang, F., Gong, C. Y., Dong, P. W., Fu, S. Z., Gu, Y. C., Guo, G., Zhao, X., Wei, Y. Q., and Qian, Z. Y. (2009). Acute toxicity evaluation of in situ gel-forming controlled drug delivery system based on biodegradable poly(epsiloncaprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) copolymer. Biomed. Mater. 4, 025002.
17. Filipe, V., Hawe, A., and Jiskoot, W. (2010). Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 27, 796-810.
18. Fischer, H. C., and Chan, W. C. (2007). Nanotoxicity: The growing need for in vivo study. Curr. Opin. Biotechnol. 18, 565-571.
19. Frozza, R. L., Bernardi, A., Paese, K., Hoppe, J. B., da Silva, T., Battastini, A. M., Pohlmann, A. R., Guterres, S. S., and Salbego, C. (2010). Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotechnol. 6, 694-703.
20. Gaumet, M., Vargas, A., Gurny, R., and Delie, F. (2008). Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur. J. Pharm. Biopharm. 69, 1-9.
21. Giknis, M. L. A., and Clifford, C. B. (2008). Clinical Laboratory Parameters for the Crl:WI (Han), Charles River Laboratories. Available at: www.criver.com. Accessed October 2010.
22. Haas, S. E., Bettoni, C. C., de Oliveira, L. K., Guterres, S. S., and Dalla Costa, T. (2009). Nanoencapsulation increases quinine antimalarial efficacy against Plasmodium berghei in vivo. Int. J. Antimicrob. Agents 34, 156-161.
23. Hauck, T. S., Anderson, R. E., Fischer, H. C., Newbigging, S., and Chan, W. C. (2010). In vivo quantum-dot toxicity assessment. Small 6, 138-144.
24. Higashisaka, K., Yoshioka, Y., Yamashita, K., Morishita, Y., Fujimura, M., Nabeshi, H., Nagano, K., Abe, Y., Kamada, H., Tsunoda, S., et al. (2011). Acute phase proteins as biomarkers for predicting the exposure and toxicity of nanomaterials. Biomaterials 32, 3-9.
25. Horak, E., Hopfer, S. M., and Sunderman, F. W., Jr. (1981). Spectrophotometric assay for urinary N-acetyl-beta-D-glucosaminidase activity. Clin. Chem. 27, 1180-1185.
26. Huang, Y., Gao, H., Gou, M., Ye, H., Liu, Y., Gao, Y., Peng, F., Qian, Z., Cen, X., and Zhao, Y. (2010). Acute toxicity and genotoxicity studies on poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) nanomaterials. Mutat. Res. 696, 101-106.
27. Hulin, M. (2002). Laboratory animal data: Quick reference guide for researchers. American Association of Laboratory Animal Science. Available at: http://www.aalas.org. Accessed October 2010.
28. Jäger, A., Stefani, V., Guterres, S. S., and Pohlmann, A. R. (2007). Physicochemical characterization of nanocapsule polymeric wall using fluorescent benzazole probes. Int. J. Pharm. 338, 297-305.
29. Jäger, E., Venturini, C. G., Poletto, F. S., Colomé, L. M., Pohlmann, J. P., Bernardi, A., Battastini, A. M., Guterres, S. S., and Pohlmann, A. R. (2009). Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J. Biomed. Nanotechnol. 5, 130-140.
30. Keck, C. M., and Müller, R. H. (2008). Size analysis of submicron particles by laser diffractometry-90% of the published measurements are false. Int. J. Pharm. 355, 150-163.
31. Kim, S. Y., Lee, Y. M., Baik, D. J., and Kang, J. S. (2003). Toxic characteristics of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) nanospheres; in vitro and in vivo studies in the normal mice. Biomaterials 24, 55-63.
32. Kroll, A., Pillukat, M. H., Hahn, D., and Schnekenburger, J. (2009). Current in vitro methods in nanoparticle risk assessment: Limitations and challenges. Eur. J. Pharm. Biopharm. 72, 370-377.
33. Li, Y. F., and Chen, C. (2011). Fate and toxicity of metallic and metal-containing nanoparticles for biomedical applications. Small 7, 2965-2980.
34. Ma, L., Zhao, J., Wang, J., Liu, J., Duan, Y., Liu, H., Li, N., Yan, J., Ruan, J., Wang, H., et al. (2009). The acute liver injury in mice caused by nanoanatase TiO2. Nanoscale Res. Lett. 4, 1275-1285.
35. Maham, A., Tang, Z., Wu, H., Wang, J., and Lin, Y. (2009). Protein-based nanomedicine platforms for drug delivery. Small 5, 1706-1721.
36. Malloy, A., and Carr, B. (2006). Nanoparticle tracking analysis-the Halo TM system. Part. Part. Syst. Charact. 23, 197.
37. Marquis, B. J., Love, S. A., Braun, K. L., and Haynes, C. L. (2009). Analytical methods to assess nanoparticle toxicity. Analyst 134, 425-439.
38. Maynard, A. D., Warheit, D. B., and Philbert, M. A. (2011). The new toxicology of sophisticated materials: Nanotoxicology and beyond. Toxicol. Sci. 120(Suppl. 1), S109-S129.
39. McClean, S., Prosser, E., Meehan, E., O'Malley, D., Clarke, N., Ramtoola, Z., and Brayden, D. (1998). Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 6, 153-163.
40. Mengual, O., Meunier, G., Cayré, I., Puech, K., and Snabre, P. (1999). TURBISCAN MA 2000: Multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta 50, 445-456.
41. Monteiro-Riviere, N. A., Inman, A. O., and Zhang, L. W. (2009). Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 234, 222-235.
42. Müller-Goymann, C. C. (2004). Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur. J. Pharm. Biopharm. 58, 343-356.
43. Mutlu, G. M., Budinger, G. R., Green, A. A., Urich, D., Soberanes, S., Chiarella, S. E., Alheid, G. F., McCrimmon, D. R., Szleifer, I., and Hersam, M. C. (2010). Biocompatible nanoscale dispersion of single-walled carbon nanotubes minimizes in vivo pulmonary toxicity. Nano Lett. 10, 1664-1670.
44. National Institutes of Health. (1985). Principles of laboratory animal care. Publication 85-23. National Institutes of Health, Bethesda, MD. Nel, A., Xia, T., Mädler, L., and Li, N. (2006). Toxic potential of materials at the nanolevel. Science 311, 622-627.
45. Oberdörster, G., Oberdörster, E., and Oberdörster, J. (2005). Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 113, 823-839.
46. Oberdörster, G., Stone, V., and Donaldson, K. (2007). Toxicology of nanoparticles: A historical perspective. Nanotoxicology 1, 2-25.
47. Organization for Economic Co-operation and Development (OECD). (1995). Test Guideline 407. Repeated Dose 28-day Oral Toxicity Study in Rodents. Available at: http://www.oecd.org. Accessed October 2010.
48. Organization for Economic Co-operation and Development (OECD). (2001). Test Guideline 420. Acute Oral Toxicity-Fixed Dose Method. Available at: http://www.oecd.org. Accessed October 2010.
49. Patlolla, A., McGinnis, B., and Tchounwou, P. (2011). Biochemical and histopathological evaluation of functionalized single-walled carbon nanotubes in Swiss-Webster mice. J. Appl. Toxicol. 31, 75-83.
50. Poletto, F. S., Jäger, E., Cruz, L., Pohlmann, A. R., and Guterres, S. S. (2008). The effect of polymeric wall on the permeability of drug-loaded nanocapsules. Mat. Sci. Eng. C. 28, 472-478.
51. Ren, D., Kratz, F., and Wang, S. W. (2011). Protein nanocapsules containing doxorubicin as a pH-responsive delivery system. Small 7, 1051-1060.
52. Sadauskas, E., Wallin, H., Stoltenberg, M., Vogel, U., Doering, P., Larsen, A., and Danscher, G. (2007). Kupffer cells are central in the removal of nanoparticles from the organism. Part. Fibre Toxicol. 4, 10.
53. Sahu, S., and Casciano, D. (2009). Nanotoxicity: From in vivo and in vitro Models to Health Risks. John Wiley & Sons, Ltd., New York, NY.
54. Salvador-Morales, C., Flahaut, E., Sim, E., Sloan, J., Green, M. L., and Sim, R. B. (2006). Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol. 43, 193-201.
55. Santamaria, A. B., and Sayes, C. M. (2010). In Nanotechnology Environmental Health and Safety Risks, Regulation and Management, p. 3-47. Elsevier, Amsterdam.
56. Sayes, C. M., Gobin, A. M., Ausman, K. D., Mendez, J., West, J. L., and Colvin, V. L. (2005). Nano-C60 cytotoxicity is due to lipid peroxidation. Biomaterials 26, 7587-7595.
57. Shah, L. K., and Amiji, M. M. (2006). Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23, 2638-2645.
58. Shaw, S. Y., Westly, E. C., Pittet, M. J., Subramanian, A., Schreiber, S. L., and Weissleder, R. (2008). Perturbational profiling of nanomaterial biologic activity. Proc. Natl. Acad. Sci. U.S.A. 105, 7387-7392.
59. Shenoy, D. B., and Amiji, M. M. (2005). Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm. 293, 261-270.
60. Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., and Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 70, 1-20.
61. Szalai, A. J., and McCrory, M. A. (2002). Varied biologic functions of C-reactive protein: Lessons learned from transgenic mice. Immunol. Res. 26, 279-287.
62. Vega-Villa, K. R., Takemoto, J. K., Yáñez, J. A., Remsberg, C. M., Forrest, M. L., and Davies, N. M. (2008). Clinical toxicities of nanocarrier systems. Adv. Drug Deliv. Rev. 60, 929-938.
63. Venturini, C. G., Jäger, E., Oliveira, C. P., Bernardi, A., Battastini, A. M. O., Guterres, S. S., and Pohlmann, A. R. (2011). Formulation of lipid core nanocapsules. Colloid Surf. A 375, 200-208.
64. Wang, Z., and Ho, P. C. (2010). Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities. Small 6, 2576-2583.
65. Woodruff, M. A., and Hutmacher, D. W. (2010). The return of a forgotten polymer- Polycaprolactone in the 21st century. Prog. Polym. Sci. 35, 1217-1256.
66. Zattoni, A., Melucci, D., Reschiglian, P., Sanz, R., Puignou, L., and Galceran, M. T. (2004). Characterization of winemaking yeast by cell number-size distribution analysis through flow field-flow fractionation with multi-wavelength turbidimetric detection. J. Chromatogr. A 1054, 293-301.